Skip to main content

Tweets

RT @ericdeinMD #RNL26 @RheumNow Uzma Haque GLP1 on pts with  SLE and diabetes Retrospective study - major improvements in MACE HR 0.66 VTE HR 0.49 Renal progession HR 0.77 Mortality HR 0.26 A major tool for rheumatic care! https://t.co/qR3HKfsugZ
Dr. John Cush @RheumNow ( View Tweet )
7 hours 14 minutes ago
RT @gibson_rheumPAC Helicobacter pylori Update: H. Pylori remains the most common chronic bacterial infection worldwide, acquired in childhood and lifelong if untreated. Its clinical impact spans far beyond dyspepsia—from ulcers to malignancy. #RNL26 tis

Dr. John Cush @RheumNow ( View Tweet )

9 hours 14 minutes ago
RT @gibson_rheumPAC Gout flares are not benign. Recent flares double MI/stroke risk and markedly increase CV mortality—making flare prevention vital.#RNL26 https://t.co/gKvqo3vFYb
Dr. John Cush @RheumNow ( View Tweet )
10 hours 13 minutes ago
RT @gibson_rheumPAC Baseline serum urate >8–9 mg/dL strongly predicts worse flares, hospitalizations, and joint damage over years. Urate level should inform urgency and intensity of therapy. #RNL26 https://t.co/4RBVXZxCCX
Dr. John Cush @RheumNow ( View Tweet )
11 hours 13 minutes ago
“The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.” - Martin Luther King, Jr.

Dr. John Cush @RheumNow ( View Tweet )

13 hours 13 minutes ago
RT @gibson_rheumPAC Arthur Kavanaugh’s RheumNow 2026: Why Do Plain X-Rays in Psoriatic Arthritis? Thought-provoking session on the role of plain radiographs in psoriatic arthritis—not as relics of the past, but as tools that still inform prognosis, function, and long-term

Dr. John Cush @RheumNow ( View Tweet )

14 hours 14 minutes ago
RT @gibson_RheumPAC Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush @RheumNow ( View Tweet )
15 hours 13 minutes ago
RT @Gibson_RheumPAC A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush @RheumNow ( View Tweet )
16 hours 13 minutes ago
RT @ericdeinMD #RNL26 GLP on Knee OA STEP 9 Trial - 68 wk Mean WOMAC improved by 41.7 pts, compared to 27.5 in PBO, improved SF-36 7% stopped due to side effects https://t.co/LJzGzzlgq6 https://t.co/5ybyUdfNjZ
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
A JAKi in GCA: 2-year efficacy and safety results in a Phase 3 study Discover how continued treatment with a JAKi impacted disease remission and steroid use. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/RVvd7y354Y
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
RT @ericdeinMD #RNL26 Haque Effect of GLP1 on Pts with RA Retrospective study Significant reduction is RA disease activity (P=0.03), VAS pain (p<0.001), weight, cholesterol and A1c But 1/3 stopped due to side effects (mostly GI) https://t.co/SNHTcRFmAX
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
RT @ericdeinMD #RNL26 Haque TOGETHER-PsA -P3B study of IXE v IXE + Tirzepatide BMI >27 + 1 wt related co-morbidity -Endpts - ACR and >10% weight reduction -ACR50 improved 33.5% compared to 20% IXE alone (p<0.05) https://t.co/KCpqbg3fHs https://t.co/zktIkdumDk
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
×